Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies
The use of intranasal chlorpheniramine shows promise in preventing COVID-19 progression to the often-debilitating post-COVID-19 syndrome PASC. The association between iCPM use and a lower prevalence of PASC symptoms is strong. Further studies are needed to establish the role of ICPM in preventing PASC.
Authors
- Anita S. Lewis
- Jarmanjeet Singh
- Jana Radwanski (ORCID: https://orcid.org/0009-0004-0413-5292)
- Mark L. Stevens (ORCID: https://orcid.org/0000-0002-1813-6403)
- Fernando Baires (ORCID: https://orcid.org/0009-0008-0682-068X)
- Miguel Sierra‐Hoffman (ORCID: https://orcid.org/0000-0002-9851-3976)
- Fernando Valerio-Pascua (ORCID: https://orcid.org/0000-0002-5880-7849)
- Franck Rahaghi (ORCID: https://orcid.org/0000-0003-0803-4005)
- Mari Tesch (ORCID: https://orcid.org/0000-0001-7216-4352)
- Syed A. A. Rizvi (ORCID: https://orcid.org/0000-0002-0162-5294)
- Estela Pineda
- Anupamjeet Kaur Sekhon
- Amy C Madril
- David Abraham Cortes-Bandy
Institutions
- University of California, Riverside (US)
- Memorial Hermann (US)
- National Autonomous University of Honduras (HN)
- Larkin University (US)
- Cleveland Clinic Florida (US)
- Kaiser Permanente Fontana Medical Center (US)
- Honduras Foundation for Agricultural Research (HN)
- Memorial Hospital (US)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1186/s12879-024-10211-8
- Citations
- 3
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 1.11